Accelerate Diagnostics Stock Market Value
| AXDX Stock | USD 1.64 0.03 1.80% |
| Symbol | Accelerate |
Accelerate Diagnostics Price To Book Ratio
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Revenue Per Share 0.665 | Quarterly Revenue Growth 0.022 | Return On Assets (0.76) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Accelerate Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Accelerate Diagnostics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Accelerate Diagnostics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Accelerate Diagnostics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Accelerate Diagnostics or generate 0.0% return on investment in Accelerate Diagnostics over 30 days. Accelerate Diagnostics is related to or competes with CVRx, Neuropace, Anika Therapeutics, Axogen, Artivion, Sight Sciences, and Orthofix Medical. Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infection... More
Accelerate Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Accelerate Diagnostics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Accelerate Diagnostics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.08 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 18.35 | |||
| Value At Risk | (7.11) | |||
| Potential Upside | 8.02 |
Accelerate Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Accelerate Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Accelerate Diagnostics' standard deviation. In reality, there are many statistical measures that can use Accelerate Diagnostics historical prices to predict the future Accelerate Diagnostics' volatility.| Risk Adjusted Performance | 0.02 | |||
| Jensen Alpha | 0.1095 | |||
| Total Risk Alpha | (0.48) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | (0.09) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Accelerate Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Accelerate Diagnostics Backtested Returns
Accelerate Diagnostics secures Sharpe Ratio (or Efficiency) of -0.0197, which signifies that the company had a -0.0197% return per unit of standard deviation over the last 3 months. Accelerate Diagnostics exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Accelerate Diagnostics' risk adjusted performance of 0.02, and Mean Deviation of 3.05 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Accelerate Diagnostics are expected to decrease at a much lower rate. During the bear market, Accelerate Diagnostics is likely to outperform the market. At this point, Accelerate Diagnostics has a negative expected return of -0.0804%. Please make sure to confirm Accelerate Diagnostics' value at risk, and the relationship between the information ratio and kurtosis , to decide if Accelerate Diagnostics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.72 |
Almost perfect reverse predictability
Accelerate Diagnostics has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Accelerate Diagnostics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Accelerate Diagnostics price movement. The serial correlation of -0.72 indicates that around 72.0% of current Accelerate Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.72 | |
| Spearman Rank Test | -0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Accelerate Diagnostics lagged returns against current returns
Autocorrelation, which is Accelerate Diagnostics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Accelerate Diagnostics' stock expected returns. We can calculate the autocorrelation of Accelerate Diagnostics returns to help us make a trade decision. For example, suppose you find that Accelerate Diagnostics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Accelerate Diagnostics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Accelerate Diagnostics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Accelerate Diagnostics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Accelerate Diagnostics stock over time.
Current vs Lagged Prices |
| Timeline |
Accelerate Diagnostics Lagged Returns
When evaluating Accelerate Diagnostics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Accelerate Diagnostics stock have on its future price. Accelerate Diagnostics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Accelerate Diagnostics autocorrelation shows the relationship between Accelerate Diagnostics stock current value and its past values and can show if there is a momentum factor associated with investing in Accelerate Diagnostics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.